Biomed Central Ltd

SHERPA: Unknown

People

  1. Aghajanian
    Aghajanian
  2. Kyi
    Kyi
  3. Makker
    Makker
  4. Iasonos
    Iasonos
  5. O'Cearbhaill
    O'Cearbhaill
  6. Zhou
    Zhou
  7. Budhu
    Budhu
  8. Grisham
    Grisham
  9. Hensley
    Hensley
  10. Liu
    Liu

Groups

  1. Department of Medicine (40)
  2. Gynecologic Medicine Service (40)
  3. Solid Tumor Oncology Division (40)
  4. GDMT, Medicine (39)
  5. Gynecology Disease Management Team (39)
  6. GSK Faculty (17)
  7. Melanoma and Immunotherapeutics Service (14)
  8. Hematology-Oncology Fellows (13)
  9. Weinberg Fellows (11)
  10. Biostatistics Service (7)
Search Within
  1. "Gynecologic Medicine Service"
Formats
  1. Meeting Abstract (20)
  2. Journal Article (17)
  3. Guidelines (2)
  4. Review (1)
Groups
  1. Department of Medicine (40)
  2. Gynecologic Medicine Service (40)
  3. Solid Tumor Oncology Division (40)
  4. GDMT, Medicine (39)
  5. Gynecology Disease Management Team (39)
  6. GSK Faculty (17)

More Groups

People
  1. Dmitriy Zamarin (20)
  2. Jedd Wolchok (11)
  3. Claire Friedman (10)
  4. Taha Merghoub (9)
  5. Carol Aghajanian (7)
  6. Chrisann Kyi (4)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (1)
  4. 2022 (5)
  5. 2021 (5)
  6. 2020 (10)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (34)
  2. BMC Women's Health (1)
  3. Breast Cancer Research (1)
  4. Genome Medicine (1)
  5. Gynecologic Oncology Research and Practice (1)
  6. Journal of Translational Medicine (1)

More Publications

Results (40)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
    Journal Article

    Movva, S.; Seier, K.; Bradic, M.; Charalambous, K.; Rosenbaum, E.; Kelly, C. M.; Cohen, S. M.; Hensley, M. L.; Avutu, V.; Banks, L. B.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
    Journal Article

    Barnicle, A.; Ray-Coquard, I.; Rouleau, E.; Cadoo, K.; Simpkins, F.; Aghajanian, C.; Leary, A.; Poveda, A.; Lheureux, S.; Pujade-Lauraine, E.; more...
    Genome Medicine (2024)

    Fulltext@MSK | Save
  • Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors
    Journal Article

    Davar, D.; Carneiro, B. A.; Dy, G. K.; Sheth, S.; Borad, M. J.; Harrington, K. J.; Patel, S. P.; Galanis, E.; Samson, A.; Agrawal, S.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: Results from Study 111/KEYNOTE-146
    Journal Article

    Makker, V.; Taylor, M. H.; Aghajanian, C.; Cohn, A. L.; Brose, M. S.; Simone, C. D.; Cao, Z. A.; Suttner, L.; Loboda, A.; Cristescu, R.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
    Guidelines

    Disis, M. L.; Adams, S. F.; Bajpai, J.; Butler, M. O.; Curiel, T.; Dodt, S. A.; Doherty, L.; Emens, L. A.; Friedman, C. F.; Gatti-Mays, M.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • MEDI1191 (IL-12 MRNA) induces peripheral and intratumoral immunostimulatory effect in patients with cutaneous or subcutaneous (c/sc) lesions
    Meeting Abstract

    Abadier, M.; Jennings, E.; Eyles, J.; Martin, P.; Pilataxi, F.; Wu, Y.; Chen, X.; Azaro, A.; Ridgway, B.; Phillips, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: Part 1 results
    Meeting Abstract

    Friedman, C.; Carvajal, R.; Davar, D.; Castanon, E.; Ascierto, P.; Calvo, E.; O'Hara, M.; Powell, S.; Shapira-Frommer, R.; Garralda, E.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
    Journal Article

    Gomez-Roca, C.; Cassier, P.; Zamarin, D.; Machiels, J. P.; Perez Gracia, J. L.; Hodi, F. S.; Taus, A.; Martinez Garcia, M.; Boni, V.; Eder, J. P.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
    Journal Article

    Schöffski, P.; Tan, D. S. W.; Martín, M.; Ochoa-de-Olza, M.; Sarantopoulos, J.; Carvajal, R. D.; Kyi, C.; Esaki, T.; Prawira, A.; Akerley, W.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: Clinical outcomes and translational biomarker analyses
    Journal Article

    Friedman, C. F.; Spencer, C.; Cabanski, C. R.; Panageas, K. S.; Wells, D. K.; Ribas, A.; Tawbi, H.; Tsai, K.; Postow, M.; Shoushtari, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save